Critical care medicine
-
Critical care medicine · May 2014
Navigating the Institutional Review Board Approval Process in a Multicenter Observational Critical Care Study.
To characterize variation in the institutional review board application process of a multicenter, observational critical care study. ⋯ In a multicenter, observational critical care study, significant variation was observed between sites in all aspects of the institutional review board evaluation and approval process. The level of difficulty was significantly higher for less experienced investigators with a trend toward longer time to institutional review board approval. Variation in institutional review board interpretation of waiver of informed consent regulations was cited as a major barrier to approval.
-
Critical care medicine · May 2014
Hypoglycemia Is Associated With Increased Postburn Morbidity and Mortality in Pediatric Patients.
The objective of this study was to determine the prevalence of hypoglycemia after burn injury and whether hypoglycemia is associated with increased postburn morbidity and mortality. ⋯ Hypoglycemic episodes correlate with injury severity and inhalation injury. When adjusted for injury severity, hypoglycemia is associated with significantly higher postburn morbidity and mortality.
-
Critical care medicine · May 2014
Observational StudyThe Effects of Different IV Fat Emulsions on Clinical Outcomes in Critically Ill Patients.
To examine the effects of different IV fat emulsions on clinical outcomes in critically ill patients. ⋯ Use of alternative IV fat emulsions in parenteral nutrition, particularly olive and fish oil, was associated with improved clinical outcomes.
-
Critical care medicine · May 2014
Deletion of Soluble Epoxide Hydrolase Attenuates Cardiac Hypertrophy via Down-Regulation of Cardiac Fibroblasts-Derived Fibroblast Growth Factor-2.
Inhibition of soluble epoxide hydrolase (Ephx2) has been shown to play a protective role in cardiac hypertrophy, but the mechanism is not fully understood. We tested the hypothesis that deletion of soluble epoxide hydrolase attenuates cardiac hypertrophy via down-regulation of cardiac fibroblasts-derived fibroblast growth factor-2. ⋯ Our present data demonstrated that deletion of soluble epoxide hydrolase prevented cardiac hypertrophy not only directly to cardiomyocytes but also to cardiac fibroblasts by reducing expression of fibroblast growth factor-2.